Citigroup Has Lowered Expectations for Hologic (NASDAQ:HOLX) Stock Price

Hologic (NASDAQ:HOLX) had its target price dropped by investment analysts at Citigroup from $80.00 to $70.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical equipment provider’s stock. Citigroup’s target price indicates a potential upside of 12.76% from the stock’s previous close.

Several other analysts have also commented on the stock. UBS Group raised their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Raymond James restated an “outperform” rating and issued a $90.00 target price (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Royal Bank of Canada dropped their price target on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. BNP Paribas raised Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Down 0.4 %

Shares of NASDAQ:HOLX opened at $62.08 on Tuesday. The stock’s 50-day moving average is $68.77 and its 200 day moving average is $75.64. The company has a market cap of $13.93 billion, a PE ratio of 19.58, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic has a 1 year low of $61.70 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Sell-side analysts anticipate that Hologic will post 4.28 EPS for the current year.

Hedge Funds Weigh In On Hologic

A number of hedge funds have recently added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Hologic in the 4th quarter worth $28,269,000. Jefferies Financial Group Inc. increased its holdings in Hologic by 141.5% in the 4th quarter. Jefferies Financial Group Inc. now owns 96,849 shares of the medical equipment provider’s stock worth $6,982,000 after buying an additional 56,742 shares in the last quarter. Forum Financial Management LP bought a new stake in Hologic in the 4th quarter worth about $324,000. Toronto Dominion Bank raised its position in Hologic by 7.9% in the 4th quarter. Toronto Dominion Bank now owns 124,308 shares of the medical equipment provider’s stock worth $8,961,000 after buying an additional 9,076 shares during the last quarter. Finally, North Star Asset Management Inc. lifted its stake in Hologic by 0.3% during the 4th quarter. North Star Asset Management Inc. now owns 252,857 shares of the medical equipment provider’s stock valued at $18,228,000 after acquiring an additional 687 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.